Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.
about
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growthCancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Molecular testing in lung cancer in the era of precision medicineTargeting the tumor vasculature to enhance T cell activityAcetylbritannilactone Modulates Vascular Endothelial Growth Factor Signaling and Regulates Angiogenesis in Endothelial CellsAn anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanomaGene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDouble-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.Vaccines targeting the neovasculature of tumorsInterleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro.Targeting angiogenesis in melanoma: prospects for the futureAngiogenesis, lymphangiogenesis, and melanoma metastasis.Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic miceAntigenic targets for renal cell carcinoma immunotherapy.Antisense therapy for restenosis following percutaneous coronary intervention.Immunotherapy of malignant brain tumors.T cell-mediated immunotherapy of metastases: state of the art in 2005.Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model.Cancer microenvironment and cancer vaccine.Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.Angiogenesis in chronic obstructive pulmonary disease: a translational appraisalImmunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Targeted therapy in renal cancer.Physiological and pathological angiogenesis in the adult pulmonary circulation.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects.Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line.A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo.A novel kinase mutation in VEGFR-1 predisposes its αC-helix/activation loop towards allosteric activation: Atomic insights from protein simulation.Antitumor immunity induced by VE-cadherin modified DC vaccine.Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.
P2860
Q24548511-6BEBAF43-7163-496C-8E7B-DF5C07E59B79Q26778150-20390751-B504-4FB4-A97C-8A67F9866059Q26824599-71E73A88-A5D9-4089-A15D-B2B28C34094AQ27026329-0E6CB6AC-6095-4CF2-9F31-679FC8FB250CQ28550070-77A043B7-95CC-4AFF-AB44-04B7345D1963Q33773435-71BEDAE0-860C-4086-815D-7F10EF489250Q34236740-C4C6FEDF-C778-4006-A03A-5E5BD4B0BD71Q34245416-CE2CE4E8-E640-4042-8DD6-436544AD99CCQ34385537-F3DEE035-8E33-452C-9ED5-DFFB65052E47Q34704905-C3F3B763-19B9-4F21-B8E1-A76DB92634EAQ34770006-0A3F9EDD-A146-4A89-8C91-C002A7135383Q34771689-F485A94E-F0BC-4E1E-BACE-4392DB4CB9A7Q35076316-367A5CF2-7B4B-471E-A104-C14A826EB3FCQ35146591-1E286CC9-8D99-4509-8D67-C69DC6B02D84Q35740182-23B4BE22-6787-4C7A-9186-05D3B85E29C7Q35925619-8B45C6C5-3740-47E5-A9C5-599A06283280Q36040825-945E9A75-F897-4987-8C23-96835B12E455Q36162929-58F7DE2E-3C2C-48DF-B693-789B272FE772Q36210864-3542491C-0310-4385-814D-C712A0D8F754Q36218573-66E6B458-02CC-486B-A2EF-724EBF79E1DFQ36284923-EBDC5E42-4E2F-4371-A322-954848F883C8Q36569004-C5C38CCB-3DF9-4831-8391-0B97A4B2A481Q36747387-BC75D6D0-69C9-47F3-B30D-011831A17445Q37058368-4B3F0601-0DF8-47EF-9C9B-C643FC136022Q37159509-D8A8AAE8-2065-4DA4-9A2E-E2AC245A1F9FQ37628695-40DBF01C-0622-4345-A5D3-90570F8DF836Q37679962-59B531B1-C45B-4AA1-B119-130E27F981ECQ37846342-162AFF15-5BF5-4E0F-86C7-C794DD46EA5DQ37905587-21CEAD40-4822-4EA9-9F8A-56FE19513B33Q38111715-04304D4D-47E7-4835-A371-0A343F009EDAQ38186064-7C475A78-FFA7-45F0-99BE-42D43632B8ADQ39203569-82CADE25-C299-42EE-BCBC-6FF994823046Q39406918-34961CA7-FAAC-4979-9809-C25EC4FB452AQ39508210-9865FE56-885F-4008-AC22-91F40558049FQ39888963-BFC7E0AA-5132-4617-97BB-94B80AA887D0Q40538646-A0968E07-F0DB-4366-97E4-40615E7048E7Q41691274-1D4F65AD-5BBB-4125-B6DD-70C10953A15FQ42366549-A38E68FD-30DD-46CD-A814-534CE2C01B5AQ44352273-C363A4D2-49A7-4067-9862-4A68B5B34DD1Q45870426-C6810F58-6F93-4C09-9FEB-7C8973AFB14F
P2860
Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Active immunization against th ...... r angiogenesis and metastasis.
@ast
Active immunization against th ...... r angiogenesis and metastasis.
@en
type
label
Active immunization against th ...... r angiogenesis and metastasis.
@ast
Active immunization against th ...... r angiogenesis and metastasis.
@en
prefLabel
Active immunization against th ...... r angiogenesis and metastasis.
@ast
Active immunization against th ...... r angiogenesis and metastasis.
@en
P2093
P2860
P356
P1476
Active immunization against th ...... r angiogenesis and metastasis.
@en
P2093
Andrea T Hooper
Angel Santiago
Daniel J Hicklin
Haijun Sun
Karen D King
Mei-Nai Wang
Peter Bohlen
Rajiv Bassi
P2860
P304
P356
10.1084/JEM.20020072
P407
P577
2002-06-01T00:00:00Z